Valeant Can Meet Mandatory Payment Deadlines, Exec Insists
This article was originally published in Scrip
Buying back shares and debt is where Valeant Pharmaceuticals International Inc. sees return on investment in the short-term, the Jefferies 2015 Global Healthcare Conference in London heard on Nov. 18. Apparently there isn't enough cash available for large scale M&A but there will continue to be smaller "tuck in" deals, according to Laurie Little, senior vp of investor relations.
Register for our free email digests: